1300 related articles for article (PubMed ID: 19196673)
1. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
[TBL] [Abstract][Full Text] [Related]
2. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP;
Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Wong NS; Fernando NH; Nixon AB; Cushman S; Aklilu M; Bendell JC; Morse MA; Blobe GC; Ashton J; Pang H; Hurwitz HI
Anticancer Res; 2011 Jan; 31(1):255-61. PubMed ID: 21273607
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
6. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V
Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
8. Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
De Bruijn MT; Raats DA; Tol J; Hinrichs J; Teerenstra S; Punt CJ; Rinkes IH; Kranenburg O
Anticancer Res; 2011 Apr; 31(4):1379-85. PubMed ID: 21508389
[TBL] [Abstract][Full Text] [Related]
9. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Tol J; Koopman M; Rodenburg CJ; Cats A; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; Mol L; Antonini NF; Punt CJ
Ann Oncol; 2008 Apr; 19(4):734-8. PubMed ID: 18272912
[TBL] [Abstract][Full Text] [Related]
10. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Loupakis F; Di Maio M; Falcone A
N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
[No Abstract] [Full Text] [Related]
12. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Modest DP; Brodowicz T; Stintzing S; Jung A; Neumann J; Laubender RP; Ocvirk J; Kurteva G; Papai Z; Knittelfelder R; Kirchner T; Heinemann V; Zielinski CC
Oncology; 2012; 83(5):241-7. PubMed ID: 22948721
[TBL] [Abstract][Full Text] [Related]
13. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
Mekenkamp LJ; Tol J; Dijkstra JR; de Krijger I; Vink-Börger ME; van Vliet S; Teerenstra S; Kamping E; Verwiel E; Koopman M; Meijer GA; van Krieken JH; Kuiper R; Punt CJ; Nagtegaal ID
BMC Cancer; 2012 Jul; 12():292. PubMed ID: 22804917
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Shitara K; Yuki S; Yoshida M; Takahari D; Utsunomiya S; Yokota T; Sato Y; Inaba Y; Tajika M; Kawai H; Yamaura H; Kato M; Yamazaki K; Komatsu Y; Muro K
Invest New Drugs; 2012 Apr; 30(2):787-93. PubMed ID: 21174225
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Pohlmann PR; Mernaugh RL; Goff LW
N Engl J Med; 2009 May; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
[No Abstract] [Full Text] [Related]
16. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
Dotan E; Meropol NJ; Burtness B; Denlinger CS; Lee J; Mintzer D; Zhu F; Ruth K; Tuttle H; Sylvester J; Cohen SJ
J Gastrointest Cancer; 2012 Dec; 43(4):562-9. PubMed ID: 22294255
[TBL] [Abstract][Full Text] [Related]
17. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Abrams TA; Meyer G; Schrag D; Meyerhardt JA; Moloney J; Fuchs CS
J Natl Cancer Inst; 2014 Feb; 106(2):djt371. PubMed ID: 24511107
[TBL] [Abstract][Full Text] [Related]
19. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW
Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313
[TBL] [Abstract][Full Text] [Related]
20. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
